{
    "clinical_study": {
        "@rank": "5120", 
        "brief_summary": {
            "textblock": "Gimatecan\u00ae is Sigma-Tau Research's new, potent, oral Topoisomerase I inhibitor. Drugs in\n      this class play a crucial role in destroying DNA replication in tumors. We are conducting\n      this study to determine the Maximum Tolerated Dose of our compound.  In addition, we plan to\n      assess the drug's ability to affect the evolution of malignant gliomas, when given as a\n      capsule, rather than by intravenous injection."
        }, 
        "brief_title": "This is an Early Study to Investigate the Effect of Gimatecan\u00ae in Adults With Malignant Glioma.", 
        "completion_date": {
            "#text": "October 2005", 
            "@type": "Actual"
        }, 
        "condition": "Malignant Glioma", 
        "condition_browse": {
            "mesh_term": "Glioma"
        }, 
        "eligibility": {
            "criteria": {
                "textblock": "Inclusion criteria:\n\n          -  Histologically confirmed diagnosis of a recurrent primary malignant glioma\n\n          -  Life expectancy of at least 3 months with normal hematological, liver and renal\n             function\n\n        Exclusion criteria:\n\n          -  Pregnant and lactating patients\n\n          -  Participation in any investigating drug study within 4 weeks preceding treatment\n             start or concurrent treatment with any other anti-cancer therapy\n\n          -  Gastrointestinal dysfunction that could alter absorption or motility"
            }, 
            "gender": "Both", 
            "healthy_volunteers": "No", 
            "maximum_age": "N/A", 
            "minimum_age": "18 Years"
        }, 
        "enrollment": {
            "#text": "59", 
            "@type": "Anticipated"
        }, 
        "firstreceived_date": "April 5, 2002", 
        "id_info": {
            "nct_id": "NCT00032903", 
            "org_study_id": "ST 01-402"
        }, 
        "intervention": {
            "intervention_name": "Gimatecan\u00ae (ST 1481)", 
            "intervention_type": "Drug"
        }, 
        "keyword": "Malignant Glioma, Camptothecin, Pharmacokinetics", 
        "lastchanged_date": "June 2, 2009", 
        "location": {
            "facility": {
                "address": {
                    "city": "Providence", 
                    "country": "United States", 
                    "state": "Rhode Island", 
                    "zip": "02903"
                }, 
                "name": "Rhode Island Hospital"
            }
        }, 
        "location_countries": {
            "country": "United States"
        }, 
        "official_title": "Oral ST1481 in Adults With Malignant Glioma: a Phase I-II Clinical Trial", 
        "overall_status": "Completed", 
        "oversight_info": {
            "authority": "United States: Food and Drug Administration"
        }, 
        "phase": "Phase 1/Phase 2", 
        "required_header": {
            "download_date": "ClinicalTrials.gov processed this data on June 04, 2014", 
            "link_text": "Link to the current ClinicalTrials.gov record.", 
            "url": "http://clinicaltrials.gov/show/NCT00032903"
        }, 
        "source": "Sigma-Tau Research, Inc.", 
        "sponsors": {
            "collaborator": {
                "agency": "Rhode Island Hospital", 
                "agency_class": "Other"
            }, 
            "lead_sponsor": {
                "agency": "Sigma-Tau Research, Inc.", 
                "agency_class": "Industry"
            }
        }, 
        "start_date": "March 2002", 
        "study_design": "Allocation: Non-Randomized, Endpoint Classification: Safety Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment", 
        "study_type": "Interventional", 
        "verification_date": "June 2009"
    }, 
    "geocoordinates": {
        "Rhode Island Hospital": "41.824 -71.413"
    }
}